Affluent Medical SA

Paris Stock Exchange:AFME.PA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🏥 Hospitals & Clinics

🩺 Medical Instruments

💻 Telehealth

Location

France

Market Cap

USD 63.06 M

Share Price

USD 1.59

Avg Daily Volume

5,235

Change (1 day)

1.10%

Change (1 year)

-8.04%

Change (YTD)

13.83%

Affluent Medical SA Revenue for the year ending December 31, 2024

Affluent Medical SA Revenue is NA for the year ending December 31, 2024. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Affluent Medical SA Revenue for the year ending December 31, 2023 was USD 1.35 M, a -5.70% change year over year.
Affluent Medical SA Revenue for the year ending December 31, 2022 was USD 1.43 M, a -13.26% change year over year.
Affluent Medical SA Revenue for the year ending December 31, 2021 was USD 1.65 M, a 64.10% change year over year.
Affluent Medical SA Revenue for the year ending December 31, 2020 was USD 1.01 M, a -37.23% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

Paris Stock Exchange: AFME.PA

Affluent Medical SA

CEO	Sebastien Ladet Ph.D.
IPO Date	June 14, 2021
Location	France
Headquarters	320, avenue Archimède
Employees	66
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🏥 Hospitals & Clinics 🩺 Medical Instruments 💻 Telehealth

Description

Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.